Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.

Background: In men with metastatic castration-resistant prostate cancer (mCRPC) with primarily bone metastases, radium-223 ( Ra) improves overall survival (OS). However, the selection of Ra is not guided by specific validated clinicopathologic factors, and thus outcomes are heterogeneous.

Patients And Methods: This retrospective survival analysis was performed in men with mCRPC treated with Ra at our cancer center.

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

Purpose: We describe the cardiovascular risk profile in a representative cohort of patients with prostate cancer treated with or without androgen deprivation therapy.

Materials And Methods: We prospectively characterized in detail 2,492 consecutive men (mean age 68 years) with prostate cancer (newly diagnosed or with a plan to prescribe androgen deprivation therapy for the first time) from 16 Canadian sites. Cardiovascular risk was estimated by calculating Framingham risk scores.